NCT05613283View on ClinicalTrials.gov

Primary Cervical Cancer Screening by Self-sampling HPV Test

Active, not recruitingOBSERVATIONAL
Enrollment

17,875

Participants

Timeline

Start Date

November 19, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2027

Conditions
Human Papillomavirus InfectionCervical CancerNegative For Intraepithelial Lesion Or MalignancyAtypical Squamous Cells of Undetermined SignificanceAtypical Squamous Cells, Cannot Rule Out High-grade Squamous Intraepithelial LesionCervical Squamous Intraepithelial LesionLow-Grade Squamous Intraepithelial LesionsHigh-Grade Squamous Intraepithelial LesionsCervical Intraepithelial Neoplasia Grade ICervical Intraepithelial Neoplasia Grade IICervical Intraepithelial Neoplasia, Grade IIIAtypical Glandular CellsAtypical Glandular Cells Not Otherwise SpecifiedAtypical Glandular Cells, Favor NeoplasticCervical Squamous Cell CarcinomaAdenocarcinoma in SituCervical Adenocarcinoma
Trial Locations (6)

Unknown

Peking University People's Hospital, Beijing

Henan Cancer Hospital, Zhengzhou

The Third Affiliated Hospital of Zhengzhou University, Zhengzhou

Hunan Provincial Maternal and Child Health Care Hospital, Changsha

Chengdu Women's and Children's Central Hospital, Chengdu

Women's Hospital School Of Medicine Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

BeijingNewBiorayTechnologyCo.,Ltd.

UNKNOWN

collaborator

Hangzhou Newhorizon Health Technology Co., Ltd.

UNKNOWN

lead

Peking University People's Hospital

OTHER